A域和C域N-糖基化对凝血因子VIII免疫原性的影响
本研究探讨凝血因子VIII(FVIII)的4个N-糖基化位点(A1域的N41和N239、A3域的N1810、C1域的N2118)对免疫原性的影响。血浆来源FVIII糖组学显示N41、N239和N1810以唾液酸化复杂糖型为主,N2118以高甘露糖型为主。质粒基因转移后各组血浆FVIII比活性相近,N41Q、N239Q和N1810Q变异体小鼠免疫反应轻度升高或相当,N2118Q变异体小鼠免疫反应显著降低,AAV介导基因转移亦证实N2118Q降低抑制物反应。
要点
- 血浆来源FVIII的N41、N239、N1810位点以唾液酸化复杂糖型为主,N2118位点以高甘露糖型为主。
- N2118Q变异体在质粒和AAV介导基因转移中均显著降低小鼠抗FVIII免疫反应。
- N2118糖基化位点周围鉴定出可激活T细胞的糖肽表位。
核心结论
- FVIII的N-糖基化可对其免疫原性产生显著影响,其中N2118位点糖基化缺失可降低抑制物反应。
研究设计与样本
- 研究采用质粒基因转移和AAV介导基因转移小鼠模型,比较B域缺失FVIII(BDD-FVIII)与4个N-糖基化位点天冬酰胺(N)突变为谷氨酰胺(Q)的FVIII变异体(N41Q、N239Q、N1810Q、N2118Q)的免疫原性。
- 对血浆来源FVIII进行糖组学分析,并用FVIII特异性增殖实验鉴定糖肽表位。
主要发现
- 糖组学分析显示血浆来源FVIII的N41、N239和N1810位点主要含唾液酸化复杂糖型,N2118位点以高甘露糖型为主。
- 质粒基因转移后各组小鼠血浆FVIII比活性保持相近。
- 与BDD-FVIII质粒处理小鼠相比,N41Q、N239Q和N1810Q FVIII变异体质粒处理小鼠免疫反应轻度升高或相当,N2118Q FVIII质粒处理小鼠免疫反应显著降低。
- AAV介导基因转移实验亦显示N2118Q FVIII变异体降低抑制物反应。
- 鉴定并表征了N2118糖基化位点周围的特定糖肽表位,该表位在FVIII特异性增殖实验中可激活T细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most significant complication in hemophilia A treatment is the formation of inhibitors against factor VIII (FVIII) protein. Glycans and glycan-binding proteins are central to a properly functioning immune system. This study focuses on whether glycosylation of FVIII plays an important role in induction and regulation of anti-FVIII immune responses. We investigated the potential roles of 4 N-glycosylation sites, including N41 and N239 in the A1 domain, N1810 in the A3 domain, and N2118 in the C1 domain of FVIII, in moderating its immunogenicity. Glycomics analysis of plasma-derived FVIII revealed that sites N41, N239, and N1810 contain mostly sialylated complex glycoforms, while high mannose glycans dominate at site N2118. A missense variant that substitutes asparagine (N) to glutamine (Q) was introduced to eliminate glycosylation on each of these sites. Following gene transfer of plasmids encoding B domain deleted FVIII (BDD-FVIII) and each of these 4 FVIII variants, it was found that specific activity of FVIII in plasma remained similar among all treatment groups. Slightly increased or comparable immune responses in N41Q, N239Q, and N1810Q FVIII variant plasmid-treated mice and significantly decreased immune responses in N2118Q FVIII plasmid-treated mice were observed when compared with BDD-FVIII plasmid-treated mice. The reduction of inhibitor response by N2118Q FVIII variant was also demonstrated in AAV-mediated gene transfer experiments. Furthermore, a specific glycopeptide epitope surrounding the N2118 glycosylation site was identified and characterized to activate T cells in an FVIII-specific proliferation assay. These results indicate that N-glycosylation of FVIII can have significant impact on its immunogenicity.
引用
- Vander Kooi A, Wang S, Fan MN, et al. Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII. Blood Adv. 2022. PMID: 35511725. doi:10.1182/bloodadvances.2021005758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。